Shareholders wreck Nycomed and Ivax merger
This article was originally published in Clinica
Executive Summary
The proposed merger between US company Ivax and Hafslund Nycomed has been wrecked by displeased shareholders of the Norwegian company. For the deal to go ahead, approval by more than two-thirds of Nycomed shareholders was required. Opposition to the merger plan had built gradually and escalated last week, says a Nycomed spokesman. Although the company believes it would receive the support of a majority of its shareholders, it considers a two-thirds majority "highly unlikely" .
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.